Ortho Clinical Diagnostics Holdings plc (OCDX)
| Market Cap | 4.41B |
| Revenue (ttm) | 1.77B |
| Net Income (ttm) | -211.90M |
| Shares Out | 237.17M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | 22.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,144,027 |
| Open | 18.76 |
| Previous Close | 19.06 |
| Day's Range | 18.53 - 19.02 |
| 52-Week Range | 15.14 - 22.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.73 (+33.0%) |
| Earnings Date | Nov 3, 2021 |
About OCDX
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in b...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for OCDX stock is "Buy." The 12-month stock price forecast is 24.73, which is an increase of 33.03% from the latest price.
News
Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021
Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4% Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively
ORTHO CLINICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequa...
NEW ORLEANS, Jan. 4, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Ortho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that m...
OCDX Stock Alert: 9 Things to Know About the Quidel Deal Sending Ortho Clinical Higher
Quidel will acquire OCDX stock for $24.68 per share and newly issued stock. The transaction will be worth a total of $6 billion.
Ortho Clinical (OCDX) Stock Alert: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Ortho Clinical D...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) to Quidel Corporation is fair ...
JD.com Is Falling, But an M&A Bid Is Lifting This Small Nasdaq Stock Thursday
Find out why the stock market could see more gains.
Quidel To Buy Ortho Clinical Diagnostics For $24.68/Share: Highlights
Quidel Corp (NASDAQ: QDEL) has agreed to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share in cash and newly issued shares in the combined company, The offer price rep...
Quidel buying Ortho Clinical Diagnostics in $6 billion deal
Quidel Corp. QDEL, -0.42% said Thursday it agreed to acquire Ortho Clinical Diagnostics Holdings Plc OCDX, +1.54% for $24.68 per share of common stock in cash and newly issued shares in the combined com...
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
SAN DIEGO & RARITAN, N.J.--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into ...
Ortho Clinical Diagnostics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
RARITAN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of it...
OCDX or DOCS: Which Is the Better Value Stock Right Now?
OCDX vs. DOCS: Which Stock Is the Better Value Option?
Ortho Clinical Diagnostics to Report Third Quarter 2021 Results on November 3, 2021
RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will repo...
Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year
Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) today ...
Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnosti...
Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwrite...
RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares
RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares
RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today annou...
Ortho Clinical Diagnostics to Participate in September Investor Conferences
RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that ...
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocaps...
-- Ortho's new VITROS® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior CO...
Ortho Clinical Diagnostics Reports Second Quarter 2021 Results
Strong Revenue Growth Drives Financial Results
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTI...
Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021
RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results fo...
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Crit...
RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic ...
Ortho Clinical Diagnostics' COVID-19 Antibody Test Gets FDA Emergency Use Approval
The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics' (NASDAQ: OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test. The company says it the first quantitative COVID-19 IgG ...
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians an...